1
|
Gregory G, Timmerman J, Lavie D, Borchmann P, Herrera AF, Minuk L, Vucinic V, Armand P, Avigdor A, Gasiorowski R, Herishanu Y, Keane C, Kuruvilla J, Palcza J, Pillai P, Marinello P, Johnson NA. P1086: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN ANTI–PD-1–NAIVE PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: AN OPEN-LABEL PHASE 1/2 STUDY. Hemasphere 2022. [PMCID: PMC9428990 DOI: 10.1097/01.hs9.0000847212.00073.29] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
2
|
Tillard M, Granier D, Reibel C, Daenens L, Armand P. Structure, characterization, and properties of BaMoO4 and BaKYb(MoO4)3 flux-grown single-crystals. J SOLID STATE CHEM 2022. [DOI: 10.1016/j.jssc.2021.122809] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
3
|
Abramson JS, Bengston EM, Redd R, Barnes JA, Takvorian T, Sokol L, Lansigan F, Armand P, Shah B, Jacobsen E, Martignetti R, Turba E, Metzler SR, Patterson V, LaCasce AS, Bello CM. MATURE RESULTS FROM A PHASE II TRIAL OF BRENTUXIMAB VEDOTIN PLUS ADRIAMYCIN AND DACARBAZINE WITHOUT RADIATION IN NON‐BULKY LIMITED STAGE CLASSICAL HODGKIN LYMPHOMA. Hematol Oncol 2021. [DOI: 10.1002/hon.110_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- J. S. Abramson
- Massachusetts General Hospital Center for Lymphoma Boston Massachusetts USA
| | - E. M. Bengston
- Dartmouth‐Hitchcock Medical Center Hematology/Oncology Lebanon New Hampshire USA
| | - R. Redd
- Dana‐Farber Cancer Institute Biostatistics Boston Massachusetts USA
| | - J. A. Barnes
- Massachusetts General Hospital Center for Lymphoma Boston Massachusetts USA
| | - T. Takvorian
- Massachusetts General Hospital Center for Lymphoma Boston Massachusetts USA
| | - L. Sokol
- Moffitt Cancer Center Hematology/Oncology Tampa USA
| | - F. Lansigan
- Dartmouth‐Hitchcock Medical Center Hematology/Oncology Lebanon New Hampshire USA
| | - P. Armand
- Dana‐Farber Cancer Institute Medical Oncology Boston USA
| | - B. Shah
- Moffitt Cancer Center Hematology/Oncology Tampa USA
| | - E. Jacobsen
- Dana‐Farber Cancer Institute Medical Oncology Boston USA
| | - R. Martignetti
- Massachusetts General Hospital Center for Lymphoma Boston Massachusetts USA
| | - E. Turba
- Moffitt Cancer Center Hematology/Oncology Tampa USA
| | - S. R. Metzler
- Dartmouth‐Hitchcock Medical Center Hematology/Oncology Lebanon New Hampshire USA
| | - V. Patterson
- Dana‐Farber Cancer Institute Medical Oncology Boston USA
| | - A. S. LaCasce
- Dana‐Farber Cancer Institute Medical Oncology Boston USA
| | - C. M. Bello
- Moffitt Cancer Center Hematology/Oncology Tampa USA
| |
Collapse
|
4
|
Ansell SM, Bröckelmann PJ, Keudell G, Lee HJ, Santoro A, Zinzani PL, Collins GP, Cohen JB, Boer JP, Kuruvilla J, Savage KJ, Trneny M, Provencio M, Jaeger U, Willenbacher W, Swanink R, Sacchi M, Shipp MA, Engert A, Armand P. NIVOLUMAB FOR RELAPSED OR REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL) AFTER AUTOLOGOUS TRANSPLANTATION: 5‐YEAR OVERALL SURVIVAL FROM THE PHASE 2 CHECKMATE 205 STUDY. Hematol Oncol 2021. [DOI: 10.1002/hon.74_2879] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- S. M. Ansell
- Mayo Clinic Division of Hematology Rochester Minnesota USA
| | - P. J. Bröckelmann
- University Hospital of Cologne Department of Internal Medicine Cologne Germany
| | - G. Keudell
- Memorial Sloan Kettering Cancer Center Department of Hematology New York New York USA
| | - H. J. Lee
- University of Texas MD Anderson Cancer Center Department of Lymphoma and Myeloma Houston Texas USA
| | - A. Santoro
- Humanitas University Humanitas Cancer Center Rozzano Milan Italy
| | - P. L. Zinzani
- University of Bologna Institute of Hematology L. e A. Seràgnoli Bologna Italy
| | - G. P. Collins
- Churchill Hospital Oxford Cancer and Haematology Centre Oxford UK
| | - J. B. Cohen
- Emory University Winship Cancer Institute Atlanta Georgia USA
| | - J. P. Boer
- Antoni van Leeuwenhoek Hospital Netherlands Cancer Institute Amsterdam Netherlands
| | - J. Kuruvilla
- University of Toronto and Princess Margaret Cancer Centre Division of Medical Oncology and Hematology Toronto Canada
| | - K. J. Savage
- BC Cancer Department of Medical Oncology Vancouver Canada
| | - M. Trneny
- Charles University in Prague and General University Hospital in Prague Department of Haematology Prague Czech Republic
| | - M. Provencio
- Hospital Universitario Puerta de Hierro Department of Medical Oncology Madrid Spain
| | - U. Jaeger
- Medical University of Vienna Clinical Department for Hematology and Hemostaseology Vienna Austria
| | - W. Willenbacher
- Innsbruck Medical University Department of Internal Medicine V Innsbruck Austria
| | - R. Swanink
- Bristol Myers Squibb Global Biometrics and Data Sciences Braine l’Alleud Belgium
| | - M. Sacchi
- Bristol Myers Squibb, Global Drug Development Princeton New Jersey USA
| | - M. A. Shipp
- Dana‐Farber Cancer Institute Department of Medical Oncology Boston Massachusetts USA
| | - A. Engert
- University Hospital of Cologne Department of Internal Medicine Cologne Germany
| | - P. Armand
- Dana‐Farber Cancer Institute Department of Medical Oncology Boston Massachusetts USA
| |
Collapse
|
5
|
Boju A, Maulion G, Saucourt J, Leval J, Ledortz J, Koudoro A, Berthomier JM, Naiim-Habib M, Armand P, Kermene V, Desfarges-Berthelemot A, Barthelemy A. Small footprint phase locking system for a large tiled aperture laser array. Opt Express 2021; 29:11445-11452. [PMID: 33984923 DOI: 10.1364/oe.420251] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/22/2021] [Accepted: 03/17/2021] [Indexed: 06/12/2023]
Abstract
A phase sensing system fitted to the control of coherent laser beam array of large cross section is experimented. It is based on the use of a fiber bundle that collects a weak part of the synthetic wavefront, that scales it down (1/40) and that reshapes it in a more compact arrangement (2D to 1D array). Then, the reconfigured beam array can be analyzed by a small footprint system making the large laser beam array easier to phase-lock. The discrete laser array wavefront transmitted by the meter long fiber bundle was stabilized thanks to a multiple arm servo loop. Laser array phase locking was further ensured by random scattering through a diffuser, associated to an alternating projection algorithm. Six fiber laser beams constituting a 110 mm diameter synthetic aperture, were phase-locked with λ/16 accuracy.
Collapse
|
6
|
Tillard M, Hermet P, Haidoux A, Granier D, Armand P. The open-framework structure of KSbGe3O9 flux-grown crystals investigated by X-ray diffraction, vibrational spectroscopy, and DFT calculations. J SOLID STATE CHEM 2021. [DOI: 10.1016/j.jssc.2020.121925] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
7
|
Armand P, Tillard M, Haidoux A, Daenens L. Single-crystal growth, structure, and optical properties of a new non-centrosymmetric germanate, RbSbGe3O9. J SOLID STATE CHEM 2020. [DOI: 10.1016/j.jssc.2020.121290] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
8
|
Laliberté F, Raut M, Duh M, Yang X, Germain G, Sen S, MacKnight S, Desai K, Armand P. REAL-WORLD HEALTHCARE RESOURCE UTILIZATION (HRU) OF CLASSICAL HODGKIN LYMPHOMA (cHL) PATIENTS (PTS) TREATED WITH ANTI-PD1 CHECKPOINT INHIBITORS IN THE UNITED STATES (US). Hematol Oncol 2019. [DOI: 10.1002/hon.175_2631] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- F. Laliberté
- Health Economics & Outcomes Research; Groupe d'analyse; Ltée Montréal Canada
| | - M. Raut
- Center for Observational and Real-World Evidence; Merck & Co., Inc.; Kenilworth United States
| | - M. Duh
- Health Economics & Outcomes Research; Analysis Group, Inc.; Boston United States
| | - X. Yang
- Center for Observational and Real-World Evidence; Merck & Co., Inc.; Kenilworth United States
| | - G. Germain
- Health Economics & Outcomes Research; Groupe d'analyse; Ltée Montréal Canada
| | - S. Sen
- Center for Observational and Real-World Evidence; Merck & Co., Inc.; Kenilworth United States
| | - S. MacKnight
- Health Economics & Outcomes Research; Groupe d'analyse; Ltée Montréal Canada
| | - K. Desai
- Center for Observational and Real-World Evidence; Merck & Co., Inc.; Kenilworth United States
| | - P. Armand
- Medical Oncology; Dana-Farber Cancer Institute; Boston United States
| |
Collapse
|
9
|
Ansell S, Bartlett N, Chen R, Herrera A, Domingo-Domenech E, Mehta A, Forero-Torres A, Garcia-Sanz R, Armand P, Devata S, Rodriguez Izquierdo A, Lossos I, Reeder C, Sher T, Choe-Juliak C, Prier K, Schwarz S, Strassz A, Alland L. INVESTIGATING SAFETY AND PRELIMINARY EFFICACY OF AFM13 PLUS PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA AFTER BRENTUXIMAB VEDOTIN FAILURE. Hematol Oncol 2019. [DOI: 10.1002/hon.134_2629] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- S.M. Ansell
- Hematology; Mayo Clinic; Rochester United States
| | - N.L. Bartlett
- Medical Oncology; Siteman Cancer Center, Washington University School of Medicine; St. Louis United States
| | - R.W. Chen
- Hematology & Hematopoietic Cell Transplantation; City of Hope; Duarte United States
| | - A. Herrera
- Hematology & Hematopoietic Cell Transplantation; City of Hope; Duarte United States
| | - E. Domingo-Domenech
- Clinical Hematology; Instituto Catalán de Oncología L'Hospitalet; Barcelona Spain
| | - A. Mehta
- Lymphoma Program; Hematology and Oncology, University of Alabama at Birmingham; Birmingham United States
| | - A. Forero-Torres
- Lymphoma Program; Hematology and Oncology, University of Alabama at Birmingham; Birmingham United States
| | - R. Garcia-Sanz
- Hematology; Hospital Universitario de Salamanca; Salamanca Spain
| | - P. Armand
- Medical oncology; Dana Farber Cancer Institute; Boston United States
| | - S. Devata
- Division of Hematology/Oncology; University of Michigan Rogel Cancer Center; Ann Arbor United States
| | | | - I.S. Lossos
- Hematology/oncology; University of Miami Sylvester Comprehensive Cancer Center; Miami United States
| | - C.B. Reeder
- Hematology; Mayo Clinic - Arizona; Phoenix United States
| | - T. Sher
- Hematology; Mayo Clinic - Floria; Jacksonville United States
| | - C. Choe-Juliak
- Clinical Development; Affimed, Inc.; New York United States
| | - K. Prier
- Clinical Operations; Affimed GmbH; Heidelberg Germany
| | - S.E. Schwarz
- Clinical Operations; Affimed GmbH; Heidelberg Germany
| | - A. Strassz
- Clinical Operations; Affimed GmbH; Heidelberg Germany
| | - L. Alland
- Clinical Development; Affimed, Inc.; New York United States
| |
Collapse
|
10
|
Ansell S, Ramchandren R, Domingo-Domènech E, Rueda A, Trněný M, Feldman T, Lee H, Provencio M, Sillaber C, Cohen J, Savage K, Willenbacher W, Sumbul A, Sacchi M, Armand P. NIVOLUMAB PLUS DOXORUBICIN, VINBLASTINE AND DACARBAZINE FOR NEWLY DIAGNOSED ADVANCED-STAGE CLASSICAL HODGKIN LYMPHOMA: CHECKMATE 205 COHORT D 2-YEAR FOLLOW-UP. Hematol Oncol 2019. [DOI: 10.1002/hon.104_2629] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- S. Ansell
- Division of Hematology; Mayo Clinic; Rochester United States
| | - R. Ramchandren
- Division of Hematology and Oncology; University of Tennessee; Knoxville United States
| | | | - A. Rueda
- Servicio de Oncología; Hospital Costa del Sol; Marbella Spain
| | - M. Trněný
- Department of Haematology; Charles University in Prague and General University Hospital in Prague; Prague Czech Republic
| | - T. Feldman
- Hematology & Oncology; Hackensack University Medical Center; Hackensack United States
| | - H. Lee
- Department of Lymphoma and Myeloma; Division of Cancer Medicine, University of Texas MD Anderson Cancer Center; Houston United States
| | - M. Provencio
- Medical Oncology Department; Hospital Universitario Puerta de Hierro; Madrid Spain
| | - C. Sillaber
- Clinical Division of Oncology; Medical University of Vienna; Vienna Austria
| | - J. Cohen
- Department of Hematology and Medical Oncology; Winship Cancer Institute, Emory University; Atlanta United States
| | - K. Savage
- Department of Pathology and Laboratory Medicine; British Columbia Cancer Center for Lymphoid Cancer; Vancouver Canada
| | - W. Willenbacher
- Department of Internal Medicine; Innsbruck University Hospital & OncoTyrol - Center for Personalized Cancer Medicine; Innsbruck Austria
| | - A. Sumbul
- Bristol-Myers Squibb; Princeton United States
| | - M. Sacchi
- Bristol-Myers Squibb; Princeton United States
| | - P. Armand
- Department of Medical Oncology; Dana-Farber Cancer Institute; Boston United States
| |
Collapse
|
11
|
Jacobson C, Redd R, Reynolds C, Fields M, Armand P, Fisher D, Jacobsen E, LaCasce A, Bose N, Ottoson N, Freedman A. A PHASE 2 CLINICAL TRIAL OF RITUXIMAB AND β-GLUCAN PGG IN RELAPSED/REFRACTORY INDOLENT B-CELL NON-HODGKIN LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.207_2631] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- C.A. Jacobson
- Medical Oncology; Dana-Farber Cancer Institute; Boston MA United States
| | - R. Redd
- Biostatistics; Dana-Farber Cancer Institute; Boston MA United States
| | - C. Reynolds
- Medical Oncology; Dana-Farber Cancer Institute; Boston MA United States
| | - M. Fields
- Medical Oncology; Dana-Farber Cancer Institute; Boston MA United States
| | - P. Armand
- Medical Oncology; Dana-Farber Cancer Institute; Boston MA United States
| | - D.C. Fisher
- Medical Oncology; Dana-Farber Cancer Institute; Boston MA United States
| | - E.D. Jacobsen
- Medical Oncology; Dana-Farber Cancer Institute; Boston MA United States
| | - A.S. LaCasce
- Medical Oncology; Dana-Farber Cancer Institute; Boston MA United States
| | - N. Bose
- Translational Immunology; Biothera Pharmaceuticals; Eagan MN United States
| | - N. Ottoson
- Translational Immunology; Biothera Pharmaceuticals; Eagan MN United States
| | - A. Freedman
- Medical Oncology; Dana-Farber Cancer Institute; Boston MA United States
| |
Collapse
|
12
|
Zinzani P, Armand P, Ribrag V, Michot J, Kuruvilla J, Zhu Y, Farooqui M, Nahar A, Moskowitz C. PHASE 1B KEYNOTE-013 STUDY OF PEMBROLIZUMAB IN PATIENTS WITH CLASSIC HODGKIN LYMPHOMA AFTER BRENTUXIMAB VEDOTIN FAILURE: RESULTS OF >4 YEARS OF FOLLOW-UP. Hematol Oncol 2019. [DOI: 10.1002/hon.106_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- P.L. Zinzani
- Oncology; Institute of Hematology, University of Bologna; Bologna Italy
| | - P. Armand
- Medical Oncology; Dana-Farber Cancer Institute, Boston; United States
| | - V. Ribrag
- Medical Oncology; Institut Gustave Roussy, Villejuif; France
| | - J. Michot
- Medical Oncology; Institut Gustave Roussy, Villejuif; France
| | - J. Kuruvilla
- Medical Oncology and Hematology; Princess Margaret Cancer Centre and University of Toronto; Toronto Canada
| | - Y. Zhu
- Medical Oncology; Merck & Co, Inc.; Kenilworth United States
| | - M. Farooqui
- Medical Oncology; Merck & Co, Inc.; Kenilworth United States
| | - A. Nahar
- Medical Oncology; Merck & Co, Inc.; Kenilworth United States
| | - C.H. Moskowitz
- Medicine; University of Miami Sylvester Comprehensive Cancer Center; Miami United States
| |
Collapse
|
13
|
Svoboda J, Armand P, Porcu P, Burke J, Stevens D, Moezi M, Bajaj M, Cull E, Wan Y, Duan C, Forslund A, Gajavelli S, Yasenchak C. TREATMENT PATTERNS, CLINICAL OUTCOMES, AND BIOMARKER EVALUATION IN CLASSICAL HODGKIN LYMPHOMA: A PROSPECTIVE OBSERVATIONAL STUDY IN US ONCOLOGY PRACTICES. Hematol Oncol 2019. [DOI: 10.1002/hon.165_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- J. Svoboda
- Lymphoma Program; University of Pennsylvania; Philadelphia United States
| | - P. Armand
- Department of Medical Oncology; Dana-Farber Cancer Institute; Boston United States
| | - P. Porcu
- Division of Medical Oncology and Hematopoietic Stem Cell Transplantation; Sidney Kimmel Cancer Center, Thomas Jefferson University; Philadelphia United States
| | - J.M. Burke
- Medical Oncology / Hematology; Rocky Mountain Cancer Centers; Aurora United States
| | - D. Stevens
- Hematology and Medical Oncology; Norton Cancer Institute; Louisville United States
| | - M. Moezi
- Medical Oncology; Hematology and Internal Medicine, Cancer Specialists of North Florida; Fleming Island United States
| | - M. Bajaj
- Medical Oncology; Illinois Cancer Care; Peoria United States
| | - E.H. Cull
- Hematology/Oncology; Greenville Health System; Greenville United States
| | - Y. Wan
- Center for Observational Research; Bristol-Myers Squibb; Princeton United States
| | - C. Duan
- Moffitt Cancer Center; Bristol-Myers Squibb; Princeton United States
| | - A. Forslund
- Precision Medicine and Translational Research in Oncology; Bristol-Myers Squibb; Princeton United States
| | | | - C. Yasenchak
- Medical Oncology and Hematology; Willamette Valley Cancer Institute and Research Center/US Oncology Research; Eugene United States
| |
Collapse
|
14
|
Caimi P, Eder J, Jacobsen E, Jacobson C, LaCasce A, Shipp M, Chapuy B, Labriola-Tomphins E, Boisserie F, Passe S, Chesné E, Pierceall W, Zhi J, DeMario M, Vaishampayan U, Dowlati A, Shapiro G, Fisher D, Armand P. A PHASE 1 STUDY OF BET INHIBITION USING RG6146 IN RELAPSED/REFRACTORY (R/R) MYC-EXPRESSING DIFFUSE LARGE B CELL LYMPHOMA (DLBCL). Hematol Oncol 2017. [DOI: 10.1002/hon.2438_134] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- P.F. Caimi
- Medicine - Hematology and Oncology; University Hospitals Seidman Cancer Center; Cleveland USA
| | - J.P. Eder
- Medicine / Section of Medical Oncology; Yale University Medical Center; New Haven USA
| | - E.D. Jacobsen
- Division of Hematologic Neoplasia; Dana Farber Cancer Institute; Boston USA
| | - C.A. Jacobson
- Division of Hematologic Neoplasia; Dana Farber Cancer Institute; Boston USA
| | - A.S. LaCasce
- Division of Hematologic Neoplasia; Dana Farber Cancer Institute; Boston USA
| | - M.A. Shipp
- Division of Hematologic Neoplasia; Dana Farber Cancer Institute; Boston USA
| | - B. Chapuy
- Division of Hematologic Neoplasia; Dana Farber Cancer Institute; Boston USA
| | - E. Labriola-Tomphins
- Roche Innovation Center New York; Roche Pharma Research and Early Development; New York USA
| | - F. Boisserie
- Roche Innovation Center New York; Roche Pharma Research and Early Development; New York USA
| | - S. Passe
- Roche Innovation Center New York; Roche Pharma Research and Early Development; New York USA
| | - E. Chesné
- Roche Innovation Center Basel; Roche Pharma Research and Early Development; Basel Switzerland
| | - W. Pierceall
- Roche Innovation Center New York; Roche Pharma Research and Early Development; New York USA
| | - J. Zhi
- Roche Innovation Center New York; Roche Pharma Research and Early Development; New York USA
| | - M. DeMario
- Roche Innovation Center New York; Roche Pharma Research and Early Development; New York USA
| | | | - A. Dowlati
- Medicine - Hematology and Oncology; University Hospitals Seidman Cancer Center; Cleveland USA
| | - G.I. Shapiro
- Division of Hematologic Neoplasia; Dana Farber Cancer Institute; Boston USA
| | - D.C. Fisher
- Division of Hematologic Neoplasia; Dana Farber Cancer Institute; Boston USA
| | - P. Armand
- Division of Hematologic Neoplasia; Dana Farber Cancer Institute; Boston USA
| |
Collapse
|
15
|
Zinzani P, Thieblemont C, Melnichenko V, Osmanov D, Bouabdallah K, Walewski J, Majlis A, Fogliatto L, Caballero Barrigón M, Christian B, Gulbas Z, Özcan M, Salles G, Shipp M, Balakumaran A, Chlosta S, Chatterjee A, Armand P. Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL): interim analysis of the KEYNOTE-170 phase 2 trial. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_49] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- P. Zinzani
- Institute of Hematology "L. e A. Seràgnoli"; University of Bologna; Bologna Italy
| | | | - V. Melnichenko
- Hematology; The National Medical Surgical Сentre named after N.I. Pirogov, Moscow; Russian Federation
| | - D. Osmanov
- Russian Academy of Medical Sciences; N.N. Blokhin Russian Oncological Research Center; Moscow Russian Federation
| | - K. Bouabdallah
- Hematology and Cell Therapy; Groupe Hospitalier du Haut Leveque; Pessac France
| | - J. Walewski
- Lymphoid Malignancy; Maria Sklodowska-Curie Institute - Oncology Center; Warsaw Poland
| | - A. Majlis
- Hematology, University of Chile; Hospital del Salvador; Santiago Chile
| | - L. Fogliatto
- Hematology; Hospital de Clinicas de Porto Alegre; Porto Alegre Brazil
| | | | - B. Christian
- Division of Hematology; Ohio State University - James Comprehensive Cancer Center; Columbus USA
| | - Z. Gulbas
- Hematologic Oncology; Anadolu Medical Center; Gebze Turkey
| | - M. Özcan
- Division of Hematology; Ankara University School of Medicine; Ankara Turkey
| | - G.A. Salles
- Hospices Civils de Lyon, Cancer Research Center of Lyon; Claude Bernard University Lyon; Pierre Benite France
| | - M.A. Shipp
- Division of Hematologic Neoplasia; Dana-Farber Cancer Institute; Boston USA
| | | | - S. Chlosta
- Clinical Research; Merck & Co., Inc.; Kenilworth USA
| | - A. Chatterjee
- Clinical Research; Merck & Co., Inc.; Kenilworth USA
| | - P. Armand
- Division of Hematologic Neoplasia; Dana-Farber Cancer Institute; Boston USA
| |
Collapse
|
16
|
Zinzani P, Fanale M, Chen R, Armand P, Johnson N, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos T, Tomita A, von Tresckow B, Shipp M, Zhang Y, Balakumaran A, Moskowitz C. PEMBROLIZUMAB MONOTHERAPY IN PATIENTS WITH PRIMARY REFRACTORY CLASSICAL HODGKIN LYMPHOMA: SUBGROUP ANALYSIS OF THE PHASE 2 KEYNOTE-087 STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_125] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- P.L. Zinzani
- Department of Experimental, Diagnostic and Specialty Medicine (DIMES); Institute of Hematology “L. e A. Seràgnoli,” University of Bologna; Bologna Italy
| | - M.A. Fanale
- Department of Lymphoma/Myeloma; The University of Texas MD Anderson Cancer Center; Houston USA
| | - R. Chen
- Department of Hematology & Hematopoietic Cell Transplantation; City of Hope National Medical Center; Duarte USA
| | - P. Armand
- Department of Hematologic Oncology; Dana-Farber Cancer Institute; Boston USA
| | - N. Johnson
- Division of Hematology; Jewish General Hospital; Montreal Canada
| | - P. Brice
- Department of Hematologic Oncology; Hôpital Saint-Louis; Paris France
| | - J. Radford
- Division of Molecular & Clinical Cancer Sciences; The University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre; Manchester UK
| | - V. Ribrag
- Department of Haematological Cancer; Institut Gustave Roussy; Villejuif France
| | - D. Molin
- Department of Immunology, Genetics and Pathology, Experimental and Clinical Oncology; Uppsala University; Uppsala Sweden
| | - T.P. Vassilakopoulos
- Department of Haematology & Bone Marrow Transplantation; National and Kapodistrian University of Athens, Laikon General Hospital; Athens Greece
| | - A. Tomita
- Department of Hematology & Oncology; Nagoya University Graduate School of Medicine *Current affiliation: Fujita Health University School of Medicine, Toyoake, Japan; Nagoya Japan
| | - B. von Tresckow
- Department of Internal Medicine; University Hospital Cologne; Cologne Germany
| | - M.A. Shipp
- Department of Hematologic Oncology; Dana-Farber Cancer Institute; Boston USA
| | - Y. Zhang
- Department of Biostatistics; LDS Oncology, Merck & Co., Inc.; Kenilworth USA
| | - A. Balakumaran
- Department of Oncology Clinical Development; Merck & Co., Inc.; Kenilworth USA
| | - C.H. Moskowitz
- Department of Hematologic Oncology; Memorial Sloan Kettering Cancer Center; New York USA
| |
Collapse
|
17
|
Fanale M, Engert A, Younes A, Armand P, Ansell S, Zinzani P, Timmerman J, Collins G, Ramchandren R, Cohen J, De Boer J, Kuruvilla J, Savage K, Trneny M, Rodig S, Shipp M, Kato K, Sumbul A, Farsaci B, Santoro A. NIVOLUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER AUTOLOGOUS TRANSPLANT: FULL RESULTS AFTER EXTENDED FOLLOW-UP OF THE PHASE 2 CHECKMATE 205 TRIAL. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_124] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- M. Fanale
- Department of Lymphoma/Myeloma; University of Texas MD Anderson Cancer Center; Houston USA
| | - A. Engert
- Department of Internal Medicine I; University Hospital of Cologne; Cologne Germany
| | - A. Younes
- Lymphoma Service; Memorial Sloan Kettering Cancer Center; New York USA
| | - P. Armand
- Medical Oncology; Dana-Farber Cancer Institute; Boston USA
| | - S. Ansell
- Division of Hematology; Mayo Clinic; Rochester USA
| | - P.L. Zinzani
- Institute of Hematology “L. e A. Seràgnoli; University of Bologna; Bologna Italy
| | - J.M. Timmerman
- Division of Hematology and Oncology; University of California, Los Angeles; Los Angeles USA
| | - G.P. Collins
- Oxford Cancer and Haematology Center; Churchill Hospital; Headington Oxford UK
| | - R. Ramchandren
- Department of Hematology/Oncology; Barbara Ann Karmanos Cancer Institute; Detroit USA
| | - J.B. Cohen
- Department of Hematology and Medical Oncology, Winship Cancer Institute; Emory University; Atlanta USA
| | - J.P. De Boer
- Department of Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital; Amsterdam Netherlands
| | - J. Kuruvilla
- Department of Medical Oncology and Hematology; University of Toronto and Princess Margaret Cancer Centre; Toronto Canada
| | - K.J. Savage
- Department of Medical Oncology; British Columbia Cancer Agency; Vancouver Canada
| | - M. Trneny
- Department of Hematology; Charles University in Prague and General University Hospital in Prague; Prague Czech Republic
| | - S. Rodig
- Department of Pathology; Brigham and Women's Hospital; Boston USA
| | - M. Shipp
- Center for Hematologic Oncology; Dana-Farber Cancer Institute; Boston USA
| | - K. Kato
- Global Clinical Research; Bristol-Myers Squibb; Lawrenceville USA
| | - A. Sumbul
- Global Biostatistics; Bristol-Myers Squibb; Lawrenceville USA
| | - B. Farsaci
- Oncology Biomarkers; Bristol-Myers Squibb; Lawrenceville USA
| | - A. Santoro
- Department of Medical Oncology and Hematology, Humanitas Cancer Center; Humanitas University; Rozzano Milan Italy
| |
Collapse
|
18
|
Zinzani P, Ribrag V, Moskowitz C, Michot J, Kuruvilla J, Bartlett N, Balakumaran A, Chatterjee A, Chlosta S, Shipp M, Armand P. PHASE 1B STUDY OF PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (RRPMBCL): UPDATED RESULTS FROM THE KEYNOTE-013 TRIAL. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_50] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- P. Zinzani
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| | - V. Ribrag
- Medicine, Institut Gustave Roussy; Villejuif France
| | - C.H. Moskowitz
- Oncology; Memorial Sloan Kettering Cancer Center; New York USA
| | - J. Michot
- Medicine, Institut Gustave Roussy; Villejuif France
| | - J. Kuruvilla
- Oncology; Princess Margaret Cancer Centre and University of Toronto; Toronto Canada
| | - N. Bartlett
- Divisions of Hematology & Oncology; Washington University; St Louis USA
| | | | - A. Chatterjee
- Clinical Research, Merck & Co., Inc.; Kenilworth USA
| | - S. Chlosta
- Clinical Research, Merck & Co., Inc.; Kenilworth USA
| | - M.A. Shipp
- Division of Hematologic Neoplasia; Dana-Farber Cancer Institute; Boston USA
| | - P. Armand
- Lymphoma Clinical Research; Dana-Farber Cancer Institute; Boston USA
| |
Collapse
|
19
|
Patryl L, Galeriu D, Armand P. Sensitivity Analysis of Rain Characteristics on HTO Concentration in Drops. Fusion Science and Technology 2017. [DOI: 10.13182/fst11-a12652] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- L. Patryl
- CEA, DAM, DIF, F91297 Arpajon, France
| | - D. Galeriu
- “Horia Hulubei” Institute for Physics & Nuclear Engineering, RO-077125 Bucharest-Magurele Roumania
| | - P. Armand
- CEA, DAM, DIF, F91297 Arpajon, France
| |
Collapse
|
20
|
Michot JM, Armand P, Ding W, Ribrag V, Christian B, Marinello P, Chlosta S, Zhang Y, Shipp M, Zinzani P. KEYNOTE-170: Phase 2 study of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL) or relapsed or refractory Richter syndrome (rrRS). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw525.49] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
21
|
Michot JM, Armand P, Ding W, Ribrag V, Christian B, Balakumaran A, Marinello P, Chlosta S, Zhang Y, Shipp M, Zinzani P. Pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL) or relapsed or refractory Richter syndrome (rrRS): Phase 2 KEYNOTE-170 study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw375.39] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
22
|
Benamrane Y, Wybo JL, Armand P. Chernobyl and Fukushima nuclear accidents: what has changed in the use of atmospheric dispersion modeling? J Environ Radioact 2013; 126:239-252. [PMID: 24077309 DOI: 10.1016/j.jenvrad.2013.07.009] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/05/2013] [Revised: 07/05/2013] [Accepted: 07/14/2013] [Indexed: 06/02/2023]
Abstract
The threat of a major accidental or deliberate event that would lead to hazardous materials emission in the atmosphere is a great cause of concern to societies. This is due to the potential large scale of casualties and damages that could result from the release of explosive, flammable or toxic gases from industrial plants or transport accidents, radioactive material from nuclear power plants (NPPs), and chemical, biological, radiological or nuclear (CBRN) terrorist attacks. In order to respond efficiently to such events, emergency services and authorities resort to appropriate planning and organizational patterns. This paper focuses on the use of atmospheric dispersion modeling (ADM) as a support tool for emergency planning and response, to assess the propagation of the hazardous cloud and thereby, take adequate counter measures. This paper intends to illustrate the noticeable evolution in the operational use of ADM tools over 25 y and especially in emergency situations. This study is based on data available in scientific publications and exemplified using the two most severe nuclear accidents: Chernobyl (1986) and Fukushima (2011). It appears that during the Chernobyl accident, ADM were used few days after the beginning of the accident mainly in a diagnosis approach trying to reconstruct what happened, whereas 25 y later, ADM was also used during the first days and weeks of the Fukushima accident to anticipate the potentially threatened areas. We argue that the recent developments in ADM tools play an increasing role in emergencies and crises management, by supporting stakeholders in anticipating, monitoring and assessing post-event damages. However, despite technological evolutions, its prognostic and diagnostic use in emergency situations still arise many issues.
Collapse
|
23
|
Tinarelli G, Mortarini L, Castelli ST, Carlino G, Moussafir J, Olry C, Armand P, Anfossi D. Review and Validation of MicroSpray, a Lagrangian Particle Model of Turbulent Dispersion. Lagrangian Modeling of the Atmosphere 2013. [DOI: 10.1029/2012gm001242] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
|
24
|
Hermet P, Lignie A, Fraysse G, Armand P, Papet P. Thermodynamic properties of the α-quartz-type and rutile-type GeO2 from first-principles calculations. Phys Chem Chem Phys 2013; 15:15943-8. [DOI: 10.1039/c3cp52741g] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
25
|
Affiliation(s)
- A. Lignie
- Institut Charles Gerhardt Montpellier, UMR5253, CNRS-UM2-ENSCM-UM1, C2M, UMII, CC1504, Place E. Bataillon, 34095 Montpellier Cedex 5, France
| | - P. Armand
- Institut Charles Gerhardt Montpellier, UMR5253, CNRS-UM2-ENSCM-UM1, C2M, UMII, CC1504, Place E. Bataillon, 34095 Montpellier Cedex 5, France
| | - P. Papet
- Institut Charles Gerhardt Montpellier, UMR5253, CNRS-UM2-ENSCM-UM1, C2M, UMII, CC1504, Place E. Bataillon, 34095 Montpellier Cedex 5, France
| |
Collapse
|
26
|
Lignie A, Armand P, Fraysse G, Haines J, Thomas P, Papet P. Flux growth of piezoelectric single crystals from the SiO 2-GeO 2binary diagram. Acta Crystallogr A 2011. [DOI: 10.1107/s0108767311082274] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
27
|
Jacobsen ED, Kim HT, Ho VT, Cutler CS, Koreth J, Fisher DC, Armand P, Alyea EP, Freedman AS, Soiffer RJ, Antin JH. A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome. Ann Oncol 2011; 22:1608-1613. [PMID: 21252059 PMCID: PMC3121969 DOI: 10.1093/annonc/mdq698] [Citation(s) in RCA: 87] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2010] [Accepted: 11/02/2010] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND The prognosis for patients with most forms of T-cell lymphoma is poor. Allogeneic hematopoietic stem-cell transplantation (HSCT) may improve the outcome. PATIENTS AND METHODS This study examines the outcome of 52 patients who underwent ablative or nonablative allogeneic HSCT for peripheral T-cell lymphoma (PTCL) or advanced mycosis fungoides/Sezary syndrome over a 12-year period at a single institution. We divided the patients into those with predominantly nodal histologies: peripheral T-cell not otherwise specified (PTCL NOS), angioimmunoblastic (AITL), or anaplastic large cell lymphoma, T/null type (systemic) (ALCL), and predominantly extranodal histologies: natural killer (NK)/T cell, enteropathy type, hepatosplenic, subcutaneous panniculitic, mycosis fungoides, or T cell or NK cell other. RESULTS Median follow-up of survivors is 49 months. Non-relapse mortality and relapse at 3 years was 27% and 43%, respectively. The incidence of grade II-IV acute graft-versus-host disease (GVHD) was 21%. The incidence of extensive chronic GVHD at 2 years was 27%. The 3-year progression-free survival was 30%: 45% in patients with predominantly nodal histologies (PTCL NOS, AITL, and ALCL) and 6% in patients with predominantly extranodal histologies (P = 0.016). Overall survival at 3 years was 41% for all patients. CONCLUSION Allogeneic HSCT can produce long-term remissions in relapsed/refractory T-cell lymphoma, especially those with nodal histologies.
Collapse
Affiliation(s)
| | - H T Kim
- Department of Biostatistics, Dana-Farber Cancer Institute, Boston, USA
| | - V T Ho
- Department of Medical Oncology
| | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Chen YB, Sun L, Kim H, Alyea E, Armand P, Attar E, Ballen K, Cutler C, Dey B, Koreth J, McAfee S, Spitzer T, Antin J, Soiffer R, Ho V. Increasing the Dose of Busulfan Results in Lower Relapse Rates and Higher Non-Relapse Mortality in Patients With MDS/AML Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant 2011. [DOI: 10.1016/j.bbmt.2010.12.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
29
|
Postow M, Kim H, Sun L, Koreth J, Armand P, Cutler C, Alyea E, Antin J, Soiffer R, Ho V. Philadelphia Chromosome Is Not an Adverse Prognostic Factor in Acute Lymphoblastic Leukemia After Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2011. [DOI: 10.1016/j.bbmt.2010.12.276] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
30
|
Cutler C, Kim H, Sun L, Sese D, Kao G, Vasquez M, Armand P, Koreth J, Ho V, Alyea E, Soiffer R, Ballen K, Ritz J, Milford E, Antin J. Anti-HLA Antibodies Predict Graft Failure, Time to Engraftment and Umbilical Cord Unit Dominance in Double Umbilical Cord Blood Transplantation. Biol Blood Marrow Transplant 2011. [DOI: 10.1016/j.bbmt.2010.12.223] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
31
|
Cutler C, Desponts C, Robbins D, North T, Goessling W, Kao G, Ritz J, Ballen K, Antin J, Spitzer T, SoifferChenY.-B.A. R, Ho V, Armand P, Koreth J, Alyea E, McAfee S, Dey B, Shoemaker D, Multani P. Ex Vivo Treatment of Hematopoietic Stem Cells With 16,16-Dimethyl Prostaglandin E2 (FT1050) Improves Engraftment and Hematopoietic Reconstitution. Biol Blood Marrow Transplant 2011. [DOI: 10.1016/j.bbmt.2010.12.224] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
32
|
Armand P, Kim HT, Mayer E, Cutler CS, Ho VT, Koreth J, Alyea EP, Antin JH, Soiffer RJ. Outcome of allo-SCT for women with MDS or AML occurring after breast cancer therapy. Bone Marrow Transplant 2010; 45:1611-7. [PMID: 20154738 DOI: 10.1038/bmt.2010.20] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Women with breast cancer who receive adjuvant therapy are at risk for developing therapy-related myelodysplastic syndrome (MDS) or AML (tMDS/AML). Patients with tMDS/AML are often referred for consideration of allogeneic hematopoietic SCT (HSCT). However, the outcomes of HSCT in such patients have not been well described. We report a retrospective study of all women who were treated with HSCT for MDS or AML at our institution between 1991 and 2008. We compared the transplantation outcomes for 24 women with a history of breast cancer with those for 271 women with de novo disease. Three-year OS and disease-free survival (DFS) for patients with a history of breast cancer were 41 and 45%, respectively. The cumulative incidences of tMDS/AML relapse and non-relapse mortality (NRM) were 38 and 17%, respectively. Those outcomes were very similar to those of patients with de novo disease. In multivariable analyses, a history of breast cancer had no impact on OS, DFS, relapse or NRM. A significant proportion of women with tAML/MDS after breast cancer treatment experience DFS after HSCT, similar to that of patients with de novo MDS or AML. This justifies consideration of HSCT for selected patients in this setting.
Collapse
Affiliation(s)
- P Armand
- Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Koreth J, Stevenson K, Kim H, McDonough S, Ho V, Alyea E, Cutler C, Armand P, Antin J, Ritz J, Soiffer R. Feasibility, Safety, Efficacy And Immunologic Impact Of Daily Ultra-Low-Dose Interleukin-2 For Steroid-Refractory Chronic Graft-Versus-Host Disease: A Phase I Study. Biol Blood Marrow Transplant 2010. [DOI: 10.1016/j.bbmt.2009.12.055] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
34
|
Armand P, Beaurain M, Rufflé B, Menaert B, Papet P. Temperature Dependence of Single-Crystal Elastic Constants of Flux-Grown α-GaPO4. Inorg Chem 2009; 48:4988-96. [DOI: 10.1021/ic900146y] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- P. Armand
- Institut Charles Gerhardt Montpellier, UMR5253 CNRS-UM2-ENSCM-UM1, PMOF, UMII, CC1504, Place E. Bataillon, 34095 Montpellier Cedex 5, France
| | - M. Beaurain
- Institut Charles Gerhardt Montpellier, UMR5253 CNRS-UM2-ENSCM-UM1, PMOF, UMII, CC1504, Place E. Bataillon, 34095 Montpellier Cedex 5, France
| | - B. Rufflé
- Laboratoire des Colloïdes, Verres et Nanomatériaux, UMR5587, UMII CC069, 34095 Montpellier Cedex 5, France,
| | - B. Menaert
- Département Matière Condensée, Matériaux et Fonctions, Institut Néel/CNRS-UJF, BP 166, 38042 Grenoble Cedex 09, France
| | - P. Papet
- Institut Charles Gerhardt Montpellier, UMR5253 CNRS-UM2-ENSCM-UM1, PMOF, UMII, CC1504, Place E. Bataillon, 34095 Montpellier Cedex 5, France
| |
Collapse
|
35
|
Cutler C, Aldridge J, Kim H, Ayanian S, Bradwin G, Revta C, Murga G, Ho V, Alyea E, Koreth J, Armand P, Richardson P, Soiffer R, Ritz J, Antin J. Prediction of VOD Using Biomarkers of Endothelial Injury. Biol Blood Marrow Transplant 2009. [DOI: 10.1016/j.bbmt.2008.12.277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
36
|
Stocki TJ, Armand P, Heinrich P, Ungar RK, D'Amours R, Korpach EP, Bellivier A, Taffary T, Malo A, Bean M, Hoffman I, Jean M. Measurement and modelling of radioxenon plumes in the Ottawa Valley. J Environ Radioact 2008; 99:1775-1788. [PMID: 18799247 DOI: 10.1016/j.jenvrad.2008.07.009] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/21/2007] [Revised: 07/10/2008] [Accepted: 07/14/2008] [Indexed: 05/26/2023]
Abstract
Since 2001 a real-time radiation monitoring network of Canadian nuclear facilities and major population centres has been implemented for response to nuclear incidents including a possible terrorist attack. Unshielded NaI(Tl) spectroscopic detectors are employed to measure gamma radiation from airborne radioactivity and radioactivity deposited on the ground. These detectors are composed of a standard 3''x3'' cylindrical NaI(Tl) spectrometers with data storage and integrated telemetry. Some of the detectors have been deployed in the Ottawa Valley near Chalk River Laboratories and Ottawa, which has a complex radioxenon environment due to the proximity of nuclear power reactors, and medical isotope facilities. Although not a health threat, these releases have provided an opportunity for the Canadian Meteorological Centre and the Commissariat à l'Energie Atomique to validate their meteorological models. The meteorological models of the two organizations are in good agreement on the origin and the source terms of these releases.
Collapse
Affiliation(s)
- T J Stocki
- Radiation Protection Bureau, 775 Brookfield Road, A.L. 6302D1, Ottawa, ON, Canada K1A 1C1.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Cutler C, Kao G, Ho V, Alyea E, Koreth J, Armand P, Dey B, Spitzer T, Soiffer R, Antin J, Ballen K. 130: Double Umbilical Cord Blood Transplantation with Reduced Intensity Conditioning and Sirolimus-Based GVHD Prophylaxis. Biol Blood Marrow Transplant 2008. [DOI: 10.1016/j.bbmt.2007.12.139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
38
|
Abstract
The structures of tripotassium digallium tris(phosphate), K3Ga2(PO4)3, and trisodium gallium bis(phosphate), Na3Ga(PO4)2, have different irregular one-dimensional alkali ion-containing channels along the a axis of the orthorhombic and triclinic unit cells, respectively. The anionic subsystems consist of vortex-linked PO4 tetrahedra and GaO4 tetrahedra or GaO5 trigonal bipyramids in the first and second structure, respectively.
Collapse
Affiliation(s)
- M Beaurain
- Institut Charles Gerhardt Montpellier, UMR 5253 CNRS-UMII, PMOF, cc 1504 Université de Montpellier II, 34095 Montpellier, France
| | | | | | | |
Collapse
|
39
|
Lee AVD, Beaurain M, Armand P. LiFe(MoO4)2, LiGa(MoO4)2and Li3Ga(MoO4)3. Acta Crystallogr C 2007; 64:i1-4. [PMID: 18216424 DOI: 10.1107/s0108270107061975] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2007] [Accepted: 11/22/2007] [Indexed: 11/11/2022] Open
|
40
|
Angot E, Parc RL, Levelut C, Beaurain M, Armand P, Cambon O, Haines J. A high-temperature Raman scattering study of the phase transitions in GaPO(4) and in the AlPO(4)-GaPO(4) system. J Phys Condens Matter 2006; 18:4315-4327. [PMID: 21690784 DOI: 10.1088/0953-8984/18/17/018] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Al(1-x)Ga(x)PO(4) solid solutions (x = 0.2, 0.3, 0.38, 0.7) and the pure AlPO(4) (x = 0) and GaPO(4) (x = 1) end members with the α-quartz-type structure were studied by Raman scattering. An investigation as a function of composition enabled the various modes to be assigned, in particular coupled and decoupled vibrations. The tetrahedral tilting modes, which have been linked to high-temperature phase transitions to β-quartz-type forms, were found to be decoupled. In addition, it is shown that Raman spectroscopy is a powerful technique for determining the gallium content of these solid solutions. Single crystals with x = 0.2, 0.38, and 1.0 (GaPO(4)) were investigated at high temperature. The composition Al(0.8)Ga(0.2)PO(4) was found to exhibit sequential transitions upon heating to the β-quartz and β-cristobalite forms at close to 993 K and 1073 K, respectively. Direct α-quartz-β-cristobalite transitions were observed for the two other compositions at close to 1083 K and 1253 K, respectively, upon heating. The spectra of the β-quartz and β-cristobalite forms indicate the presence of significant disorder. Back transformation to the α-quartz-type form occurred readily with a hysteresis of less than 100 K for the composition x = 0.38 and for pure GaPO(4). Rapid cooling was necessary to obtain the metastable α-cristobalite form. In contrast, for Al(0.80)Ga(0.20)PO(4), the α-cristobalite form was obtained even upon slow cooling.
Collapse
Affiliation(s)
- E Angot
- Laboratoire des Colloïdes, des Verres et des Nanomatériaux, UMR CNRS 5587, Université Montpellier II, cc026, Place E Bataillon, F-34095 Montpellier Cedex 5, France. Laboratoire de Physicochimie de la Matière Condensée, UMR CNRS 5617, Université Montpellier II, cc003, Place E Bataillon, F-34095 Montpellier Cedex 5, France
| | | | | | | | | | | | | |
Collapse
|
41
|
|
42
|
Armand P, Kirshenbaum K, Falicov A, Dunbrack RL, Dill KA, Zuckermann RN, Cohen FE. Chiral N-substituted glycines can form stable helical conformations. Fold Des 2001; 2:369-75. [PMID: 9427011 DOI: 10.1016/s1359-0278(97)00051-5] [Citation(s) in RCA: 153] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
BACKGROUND Short sequence-specific heteropolymers of N-substituted glycines (peptoids) have emerged as promising tools for drug discovery. Recent work on medium-length peptoids containing chiral centers in their sidechains has demonstrated the existence of stable chiral conformations in solution. In this report, we explore the conformational properties of these N alpha chiral peptoids by molecular mechanics calculations and we propose a model for the solution conformation of an octamer of (S)-N-(1-phenylethyl)glycine. RESULTS Molecular mechanics calculations indicate that the presence of N-substituents in which the N alpha carbons are chiral centers has a dramatic impact on the available backbone conformations. These results are supported by semi-empirical quantum mechanical calculations and coincide qualitatively with simple steric considerations. They suggest that an octamer of (S)-N-(1-phenylethyl)glycine should form a right-handed helix with cis amide bonds, similar to the polyproline type I helix. This model is consistent with circular dichorism studies of these molecules. CONCLUSIONS Peptoid oligomers containing chiral centers in their sidechains present a new structural paradigm that has promising implications for the design of stably folded molecules. We expect that their novel structure may provide a scaffold to create heteropolymers with useful functionality.
Collapse
Affiliation(s)
- P Armand
- Chiron Corporation, Emeryville, CA 94608, USA
| | | | | | | | | | | | | |
Collapse
|
43
|
Geffray L, Poynard JP, Collet T, Armand P, Verdon R. [A "diagnosis of goldsmith"]. Rev Med Interne 2000; 21 Suppl 3:326s-329s. [PMID: 10916845 DOI: 10.1016/s0248-8663(00)89259-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Affiliation(s)
- L Geffray
- Service de médecine interne, centre hospitalier Robert-Bisson, Lisieux
| | | | | | | | | |
Collapse
|
44
|
Armand P, Kirshenbaum K, Goldsmith RA, Farr-Jones S, Barron AE, Truong KT, Dill KA, Mierke DF, Cohen FE, Zuckermann RN, Bradley EK. NMR determination of the major solution conformation of a peptoid pentamer with chiral side chains. Proc Natl Acad Sci U S A 1998; 95:4309-14. [PMID: 9539733 PMCID: PMC22485 DOI: 10.1073/pnas.95.8.4309] [Citation(s) in RCA: 268] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Polymers of N-substituted glycines ("peptoids") containing chiral centers at the alpha position of their side chains can form stable structures in solution. We studied a prototypical peptoid, consisting of five para-substituted (S)-N-(1-phenylethyl)glycine residues, by NMR spectroscopy. Multiple configurational isomers were observed, but because of extensive signal overlap, only the major isomer containing all cis-amide bonds was examined in detail. The NMR data for this molecule, in conjunction with previous CD spectroscopic results, indicate that the major species in methanol is a right-handed helix with cis-amide bonds. The periodicity of the helix is three residues per turn, with a pitch of approximately 6 A. This conformation is similar to that anticipated by computational studies of a chiral peptoid octamer. The helical repeat orients the amide bond chromophores in a manner consistent with the intensity of the CD signal exhibited by this molecule. Many other chiral polypeptoids have similar CD spectra, suggesting that a whole family of peptoids containing chiral side chains is capable of adopting this secondary structure motif. Taken together, our experimental and theoretical studies of the structural properties of chiral peptoids lay the groundwork for the rational design of more complex polypeptoid molecules, with a variety of applications, ranging from nanostructures to nonviral gene delivery systems.
Collapse
Affiliation(s)
- P Armand
- Chiron Technologies, Chiron Corporation, 4560 Horton Street, Emeryville, CA 94608, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Kirshenbaum K, Barron AE, Goldsmith RA, Armand P, Bradley EK, Truong KT, Dill KA, Cohen FE, Zuckermann RN. Sequence-specific polypeptoids: a diverse family of heteropolymers with stable secondary structure. Proc Natl Acad Sci U S A 1998; 95:4303-8. [PMID: 9539732 PMCID: PMC22484 DOI: 10.1073/pnas.95.8.4303] [Citation(s) in RCA: 379] [Impact Index Per Article: 14.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
We have synthesized and characterized a family of structured oligo-N-substituted-glycines (peptoids) up to 36 residues in length by using an efficient solid-phase protocol to incorporate chemically diverse side chains in a sequence-specific fashion. We investigated polypeptoids containing side chains with a chiral center adjacent to the main chain nitrogen. Some of these sequences have stable secondary structure, despite the achirality of the polymer backbone and its lack of hydrogen bond donors. In both aqueous and organic solvents, peptoid oligomers as short as five residues give rise to CD spectra that strongly resemble those of peptide alpha-helices. Differential scanning calorimetry and CD measurements show that polypeptoid secondary structure is highly stable and that unfolding is reversible and cooperative. Thermodynamic parameters obtained for unfolding are similar to those obtained for the alpha-helix to coil transitions of peptides. This class of biomimetic polymers may enable the design of self-assembling macromolecules with novel structures and functions.
Collapse
Affiliation(s)
- K Kirshenbaum
- Department of Pharmaceutical Chemistry, University of California, San Francisco, CA 94143
| | | | | | | | | | | | | | | | | |
Collapse
|
46
|
|
47
|
|
48
|
Patat A, Berlin I, Durrieu G, Armand P, Fitoussi S, Molinier P, Caille P. Pressor effect of oral tyramine during treatment with befloxatone, a new reversible monoamine oxidase-A inhibitor, in healthy subjects. J Clin Pharmacol 1995; 35:633-43. [PMID: 7665725 DOI: 10.1002/j.1552-4604.1995.tb05022.x] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
The interaction between tyramine and befloxatone, a new selective, reversible monoamine oxidase-A (MAO-A) inhibitor, was studied in a single-blind, parallel-group study in 30 healthy male volunteers whose fasting tyramine 30 dose (Tyr30) was 400 or 600 mg. Each subject completed a placebo run-in period followed by a befloxatone period. Befloxatone was given in repeated doses according to one of three regimens: befloxatone 20 mg once daily at the end of a meal rich in tyramine or befloxatone 10 or 20 mg twice daily 2 hours before a meal rich in tyramine. Subjects were given increasing daily doses of tyramine mixed with the meal, until a systolic blood pressure increase of at least 30 mm Hg was achieved (Tyr30). The mean Tyr30 decreased from 1220 mg (range, 600-1800 mg) during placebo to 290 mg (range, 150-500 mg) during befloxatone 20 mg once daily, 250 mg (range, 100-300) during befloxatone 10 mg twice daily, and 155 mg (range, 100-250 mg) during befloxatone 20 mg twice daily; corresponding to a potentiation factor of 5.2-, 6.5-, and 7.9-fold, respectively. The extent and the duration of the systolic blood pressure increase did not significantly differ between the placebo and the befloxatone regimens, except for a longer duration with the 20-mg twice daily regimen. These results are similar to those reported with the therapeutic dosage of other selective MAO-A inhibitors. They suggest that there would be little risk of hypertensive crisis in patients treated in clinical studies with befloxatone, and thus dietary restrictions appear to be unnecessary when the drug is given in a regimen of up to 20-mg once daily after meals.
Collapse
Affiliation(s)
- A Patat
- Synthélabo Recherche, Bagneux, France
| | | | | | | | | | | | | |
Collapse
|
49
|
Allain P, Le Bouil A, Turcant A, Molinier P, Armand P, Andrianiriana F. [Pharmacokinetics of low-dose lithium in healthy volunteers]. Therapie 1994; 49:321-4. [PMID: 7878598] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
The pharmacokinetics of lithium in healthy volunteers receiving low doses of lithium as Lithium Oligosol by sublingual route were investigated in two randomized crossover studies (lithium vs placebo) with a two week wash-out period. In the first study, 8 volunteers received a single dose (1.68 mg) of lithium and in the second 8 another volunteers received repetitive doses of lithium (0.56 mg twice a day) during 11 days. The plasma concentration of lithium was determined by an electrothermal atomic absorption spectrometry. The plasma concentrations of lithium measured during the placebo period were about 1 microgram/L, the peak concentration was 99.4 +/- 22.2 micrograms/L in the single dose study and 49.6 +/- 5.4 micrograms/L in the multiple doses study. In this last one, the residual plasma levels of lithium were between 20 and 25 micrograms/L. The pharmacokinetics parameters measured were: T1/2 = 22.6 +/- 3.1 h; Vd/F = 0.70 +/- 0.09 L/kg and Cl/F = 1.53 +/- 0.12 L/h. The plasma concentrations of lithium are strictly dependent on intake from food or drugs.
Collapse
Affiliation(s)
- P Allain
- Laboratoire de Pharmacologie et Toxicologie, Centre hospitalier universitaire, Angers
| | | | | | | | | | | |
Collapse
|
50
|
Armand P, Knapp AC, Hirsch AJ, Wieschaus EF, Cole MD. A novel basic helix-loop-helix protein is expressed in muscle attachment sites of the Drosophila epidermis. Mol Cell Biol 1994; 14:4145-54. [PMID: 8196652 PMCID: PMC358780 DOI: 10.1128/mcb.14.6.4145-4154.1994] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
We have found that a novel basic helix-loop-helix (bHLH) protein is expressed almost exclusively in the epidermal attachments sites for the somatic muscles of Drosophila melanogaster. A Drosophila cDNA library was screened with radioactively labeled E12 protein, which can dimerize with many HLH proteins. One clone that emerged from this screen encoded a previously unknown protein of 360 amino acids, named delilah, that contains both basic and HLH domains, similar to a group of cellular transcription factors implicated in cell type determination. Delilah protein formed heterodimers with E12 that bind to the muscle creatine kinase promoter. In situ hybridization with the delilah cDNA localized the expression of the gene to a subset of cells in the epidermis which form a distinct pattern involving both the segmental boundaries and intrasegmental clusters. This pattern was coincident with the known sites of attachment of the somatic muscles to tendon cells in the epidermis. delilah expression persists in snail mutant embryos which lack mesoderm, indicating that expression of the gene was not induced by attachment of the underlying muscles. The similarity of this gene to other bHLH genes suggests that it plays an important role in the differentiation of epidermal cells into muscle attachment sites.
Collapse
Affiliation(s)
- P Armand
- Department of Molecular Biology, Princeton University, Princeton, New Jersey 08544-1014
| | | | | | | | | |
Collapse
|